trastuzumab-dkst

Biosimilars for Cancer Drugs Move AheadBiosimilar to Herceptin Is Approved and Neulasta biosimilar does well in studies.
New cancer biosimilar could net major sales
New cancer biosimilar could net major salesA new biosimilar to the cancer drug Herceptin, which raked in $2.5 billion in US sales last year, is expected to produce blockbuster sales in the US.